Tempus AI, Inc. $TEM Stake Decreased by Venture Visionary Partners LLC

Venture Visionary Partners LLC lessened its holdings in shares of Tempus AI, Inc. (NASDAQ:TEM) by 20.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 45,474 shares of the company’s stock after selling 11,894 shares during the period. Venture Visionary Partners LLC’s holdings in Tempus AI were worth $2,685,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Tempus AI by 22.1% during the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock valued at $762,032,000 after buying an additional 1,706,837 shares during the last quarter. Krane Funds Advisors LLC raised its holdings in shares of Tempus AI by 218.2% during the third quarter. Krane Funds Advisors LLC now owns 28,230 shares of the company’s stock valued at $2,427,000 after buying an additional 19,358 shares during the last quarter. Pictet Asset Management Holding SA raised its holdings in shares of Tempus AI by 291.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 48,488 shares of the company’s stock valued at $2,948,000 after buying an additional 36,096 shares during the last quarter. Aberdeen Group plc raised its holdings in shares of Tempus AI by 64.2% during the fourth quarter. Aberdeen Group plc now owns 263,004 shares of the company’s stock valued at $15,530,000 after buying an additional 102,878 shares during the last quarter. Finally, Bogart Wealth LLC raised its holdings in Tempus AI by 365,087.5% during the fourth quarter. Bogart Wealth LLC now owns 58,430 shares of the company’s stock worth $3,450,000 after purchasing an additional 58,414 shares in the last quarter. Institutional investors own 24.22% of the company’s stock.

Tempus AI Price Performance

Shares of NASDAQ:TEM opened at $52.32 on Tuesday. The company has a debt-to-equity ratio of 2.96, a current ratio of 3.31 and a quick ratio of 3.15. The stock has a market cap of $9.40 billion, a price-to-earnings ratio of -30.42 and a beta of 3.64. Tempus AI, Inc. has a 12 month low of $41.73 and a 12 month high of $104.32. The stock’s 50 day moving average price is $49.42 and its 200 day moving average price is $56.51.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.08. The firm had revenue of $348.12 million for the quarter, compared to analyst estimates of $345.44 million. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The firm’s quarterly revenue was up 36.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.24) earnings per share. Equities research analysts anticipate that Tempus AI, Inc. will post -1.35 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on TEM shares. BTIG Research reissued a “buy” rating and set a $80.00 target price on shares of Tempus AI in a report on Monday, June 1st. Morgan Stanley dropped their target price on Tempus AI from $85.00 to $70.00 and set an “overweight” rating on the stock in a report on Tuesday, March 3rd. Jefferies Financial Group started coverage on Tempus AI in a report on Monday, April 13th. They set an “underperform” rating and a $35.00 target price on the stock. Wall Street Zen raised Tempus AI from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Finally, TD Cowen boosted their target price on Tempus AI from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Nine analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Tempus AI currently has a consensus rating of “Hold” and a consensus target price of $68.64.

Insider Transactions at Tempus AI

In other Tempus AI news, CAO Ryan M. Bartolucci sold 4,116 shares of Tempus AI stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total value of $181,392.12. Following the transaction, the chief accounting officer owned 74,041 shares in the company, valued at approximately $3,262,986.87. The trade was a 5.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ryan Fukushima sold 13,550 shares of Tempus AI stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total transaction of $597,148.50. Following the completion of the transaction, the chief executive officer owned 603,558 shares in the company, valued at approximately $26,598,801.06. This trade represents a 2.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 558,557 shares of company stock valued at $26,611,939 in the last 90 days. 24.26% of the stock is owned by corporate insiders.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.